Pay in 4 interest-free payments of $5.43 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Study on demand with a CPD certificate on completion
Following a thorough analysis of our previous Phase IIb data and trial design, we are confident that with the preferred modified release formulation and optimized future trial design, we can advance a competitive oral GLP-1 molecule into registration-enabling studies to meet the ongoing medical needs of people living with obesity. The ongoing open-label, randomized study is assessing the pharmacokinetics and safety of immediate- and modified-release formulations of danuglipron administered orally in healthy adults aged 18 years or older
Zepbound, while newer and with less long-term data, shows promise for sustained weight loss
Both are glucagon-like peptide-1 (GLP-1) receptor agonists with distinct mechanisms: semaglutide targets GLP-1 receptors, while tirzepatide combines GLP-1 and GIP receptor activation, potentially offering greater weight reduction in some patients
US$ 20.25
US$ 21.34
US$ 20.28
US$ 21.76
